drugset / Trial / NCT02339350
Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Treatment of pediatric acute lymphoblastic leukemia (ALL) has advanced and the overall survival exceeds 80% nowadays. However the overall survival of high risk ALL remains 75-90%, thus recent studies focus on treatment intensification according to the risk group. According to the previous reports, we designed a multicenter prospective trial for pediatric ALL.
Timeline
- Start
- 2015-01
- Primary completion
- 2023-04
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intrathecal |
| Subject | Hydrocortisone | Other / unclassified | — | Intrathecal |
| Subject | Methotrexate | Small molecule | 5000 mg/m2 | Intravenous |